. . . "NCT04557059" . . . . "klinisch onderzoek"@nl . . . . . . . . . . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants"@en . "2027-11-29T00:00:00Z"^^ . "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants"@en . "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants"@en . "2020-10-14T00:00:00Z"^^ . "ensayu cl\u00EDnicu"@ast . . . . . "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants"@nl . "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants"@nl . "A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants"@nl . . . "412"^^ . "PRIMORDIUM"@en . . . . "\u4E34\u5E8A\u8BD5\u9A8C"@zh . "ensayo cl\u00EDnico"@es . . . . . "clinical trial"@en . . . . "A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, With an Observational Follow-up of PSMA-PET-Negative Patients"@en . . . . . . . . "\u056F\u056C\u056B\u0576\u056B\u056F\u0561\u056F\u0561\u0576 \u0583\u0578\u0580\u0571\u0561\u0580\u056F\u0578\u0582\u0574"@hy . . . . "18"^^ . . . .